NextEra Energy, Inc. vs TransMedics Group Inc — how do they compare? NextEra Energy, Inc. trades at $85.8 (market cap $178.85B), while TransMedics Group Inc trades at $89.69 (market cap $3.10B). The key difference: NextEra Energy, Inc. is far larger — about 57.7× TransMedics Group Inc's market cap, and NextEra Energy, Inc. pays a 2.91% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NEE | TMDX | |
|---|---|---|
Market Cap | $178.85B | $3.10B |
Sector | Utilities | Technology |
52-Week High | $97.88 | $150.42 |
52-Week Low | $69.77 | $61.99 |
Enterprise Value | $286.18B | $3.49B |
Dividend Yield | 2.91% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMDX trades at $83.89, up 4.59% today, with a bullish technical signal from moving averages and strong support at $81. The company reported a Q2 2026 earnings miss ($0.44 actual vs. $0.50 expected) but beat revenue expectations, with 2025 net income at $190.29M. Analyst consensus is a Buy with a $99.57 price target, though recent news highlights a legal investigation into fiduciary duties.
Outlook remains positive due to raised revenue guidance and institutional interest, but risks include earnings volatility, margin pressure, and legal scrutiny. The stock's valuation multiples suggest growth expectations, yet execution on cost control and international expansion will be critical for sustained upside.
Trailing returns across standard periods
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →